SCHEMBL3017923

SCHEMBL3017923

O=S(=O)(c1ccc(Cl)cc1)C1CCN(c2nc(Cc3ccc(Cl)c(Cl)c3)cs2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 4/20 0.38
HTR2A P28223 2/20 0.38
KCNH2 Q12809 2/20 0.38
LMNA P02545 2/20 0.38
DRD2 P14416 1/20 0.38
HTR2C P28335 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
AR P10275 2/20 0.38
GAA P10253 1/20 0.36
EPHX2 P34913 1/20 0.35
RAB9A P51151 3/20 0.35
NPC1 O15118 2/20 0.35
MAPK1 P28482 2/20 0.35
NR1I3 Q14994 2/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017117 0.94 MAPT (0.38) MAPTSMN1; SMN2HTR2AKCNH2LMNA
SCHEMBL3013801 0.94 L3MBTL1 (0.39) MAPTSMN1; SMN2HTR2ALMNAL3MBTL1
SCHEMBL3009908 0.93 LMNA (0.38) MAPTSMN1; SMN2HTR2ALMNAL3MBTL1
SCHEMBL3017508 0.92 LMNA (0.37) MAPTSMN1; SMN2HTR2ALMNAL3MBTL1
SCHEMBL3009192 0.92 LMNA (0.37) MAPTSMN1; SMN2HTR2AKCNH2LMNA
SCHEMBL3022387 0.92 HTR2A (0.43) MAPTSMN1; SMN2HTR2AKCNH2LMNA
SCHEMBL3012727 0.92 ALDH1A1 (0.40) MAPTSMN1; SMN2LMNAL3MBTL1AR
SCHEMBL3014815 0.92 L3MBTL1 (0.41) MAPTSMN1; SMN2HTR2AKCNH2LMNA
SCHEMBL3017031 0.92 MAPT (0.42) MAPTSMN1; SMN2HTR2AKCNH2LMNA
SCHEMBL3011420 0.92 HTR2A (0.42) MAPTSMN1; SMN2HTR2AKCNH2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885SMN1; SMN2 1/4885HTR2A 752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.